Prostate Cancer Clinical Trial

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Summary

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

View Full Description

Full Description

Subjects will receive product as described in the sipuleucel-T approved label. The registry will be strictly observational and thus no additional clinical visits or laboratory tests will be conducted beyond normal clinical practice. Investigators will be asked to record information that becomes available in the normal course of clinical management.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

subjects must be at least 18 years of age
subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment
subjects must understand and sign an informed consent form

Exclusion Criteria:

none

Study is for people with:

Prostate Cancer

Estimated Enrollment:

1976

Study ID:

NCT01306890

Recruitment Status:

Completed

Sponsor:

Dendreon

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 309 Locations for this study

See Locations Near You

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

1976

Study ID:

NCT01306890

Recruitment Status:

Completed

Sponsor:


Dendreon

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider